Research programme: dopamine D4 receptor antagonists - Sanofi-Aventis/NPS Allelix

Drug Profile

Research programme: dopamine D4 receptor antagonists - Sanofi-Aventis/NPS Allelix

Alternative Names: Dopamine D4 receptor antagonists research programme - Aventis/NPS Allelix

Latest Information Update: 24 Jan 2005

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NPS Allelix; sanofi-aventis
  • Developer sanofi-aventis
  • Class
  • Mechanism of Action Dopamine D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 24 Jan 2005 Discontinued - Preclinical for Schizophrenia in USA (unspecified route)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 10 Feb 2000 Allelix Biopharmaceuticals has merged with NPS Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top